MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: International Trial Of Novel Breast Cancer Drug

Back to breast cancer blog Blogs list Cancer blog  


Subscribe To Breast Cancer Blog RSS Feed  RSS content feed What is RSS feed?

International Trial Of Novel Breast Cancer Drug

International Trial Of Novel Breast Cancer Drug
A clinical trial of a new targeted breast cancer drug, led by physicians at Massachusetts General Hospital (MGH) Cancer Center, has begun enrolling patients. The TEACH (Tykerb Evaluation After CHemotherapy) trial will investigate the experimental drug Tykerb (lapatinib) in patients with early-stage, HER2-positive breast cancer who have not been treated with Herceptin, another targeted drug used for the same type of tumor. The MGH is the lead institution for the international trial, which is being sponsored by GlaxoSmithKline, the manufacturer of Tykerb.

"This trial represents another step toward understanding the role of targeted therapies in extending disease-free survival," said Paul Goss, MD, PhD, director of Breast Cancer Research at the MGH Cancer Center, who proposed the TEACH study and chairs the International Steering Committee.

About one quarter of patients with breast cancer have tumors that overexpress or produce too a number of copies of a receptor molecule called HER2. Because cellular growth is stimulated by the overactivity of this molecule, which also is called ErbB2, these tumors are more likely to recur and are less responsive to hormone-based therapys. Herceptin, a monoclonal antibody that blocks the HER2 receptor, is approved by the FDA as an adjuvant therapy - given along with chemotherapy after surgical removal and/or radiation treatment - for early-stage, node-positive and HER2-positive tumors as well as for metastatic tumors.

Tykerb blocks both the HER2/ErbB2 receptor and a related molecule called ErbB1. Earlier clinical trials have indicated that it may have advantages over Herceptin in many settings correlation to therapy of HER2-positive breast cancer without significant side effects. Tykerb has still not received approval from the U.S. Food and Drug Administration, and the TEACH study is a Phase III trial of its use in patients with early-stage HER2-positive tumors. To enroll in the study - which is being conducted at 450 sites around the world - patients must have completed adjuvant chemotherapy but not have received Herceptin. Study participants will be randomized to receive a daily oral dose of either Tykerb or a placebo for up to one year.

"The TEACH study will be the first to investigate the use of a dual ErbB1 and ErbB2 inhibitor as an adjuvant therapy for women with HER2-positive breast cancer, who are at a high risk of their disease recurring," says Goss.

"The concept of the TEACH study arose from our clinics," says Beverly Moy, MD, a medical oncologist at the MGH Breast Center and a member of the TEACH International Steering Committee."We have patients with HER2-positive breast cancer who had never received Herceptin because they were diagnosed before we knew about the benefits of Herceptin in early-stage breast cancer. The results of this study could reveal whether the targeted treatment Tykerb could benefit women several years after the initial diagnosis of breast cancer".


Posted by: Janet    Source




Did you know?
A clinical trial of a new targeted breast cancer drug, led by physicians at Massachusetts General Hospital (MGH) Cancer Center, has begun enrolling patients. The TEACH (Tykerb Evaluation After CHemotherapy) trial will investigate the experimental drug Tykerb (lapatinib) in patients with early-stage, HER2-positive breast cancer who have not been treated with Herceptin, another targeted drug used for the same type of tumor. The MGH is the lead institution for the international trial, which is being sponsored by GlaxoSmithKline, the manufacturer of Tykerb.

Medicineworld.org: International Trial Of Novel Breast Cancer Drug

BREAST CANCER MAIN| Home| Breast cancer news| Common terms| Breast cancer treatment| Breast cancer treatment by stage| Mammogram and breast cancer screening| Surgical treatment of breast cancer| Chemotherapy of breast cancer| Chemo drugs used in breast cancer| Doxorubicin| Cyclophosphamide| Methotrexate| Hormonal therapy of breast cancer| Radiation therapy of breast cancer| Monoclonal therapy| High dose chemotherapy for breast cancer| Recurrent breast cancer| Bisphosphonates and breast cancer| Pregnancy and breast cancer| Risk factors for breast cancer| Risk details| My risk| Comprehensive breast cancer information| Breast cancer statistics| African Americans and breast cancer| Ashkenazi and breast cancer| Asians| Hispanic| Men| Native Americans| Older women and breast cancer| Younger women| Pregnant women and breast cancer| BRCA|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.